ATE427745T1 - Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus - Google Patents
Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmusInfo
- Publication number
- ATE427745T1 ATE427745T1 AT02789421T AT02789421T ATE427745T1 AT E427745 T1 ATE427745 T1 AT E427745T1 AT 02789421 T AT02789421 T AT 02789421T AT 02789421 T AT02789421 T AT 02789421T AT E427745 T1 ATE427745 T1 AT E427745T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- therapies
- compositions
- treating
- alcoholsm
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 239000003187 aldehyde dehydrogenase inhibitor Substances 0.000 title 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 abstract 1
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33890101P | 2001-11-05 | 2001-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE427745T1 true ATE427745T1 (de) | 2009-04-15 |
Family
ID=23326616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02789421T ATE427745T1 (de) | 2001-11-05 | 2002-11-04 | Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20030087814A1 (de) |
| EP (1) | EP1441708B1 (de) |
| AT (1) | ATE427745T1 (de) |
| AU (1) | AU2002354017B2 (de) |
| CA (1) | CA2463987C (de) |
| DE (1) | DE60231896D1 (de) |
| DK (1) | DK1441708T3 (de) |
| NZ (1) | NZ532583A (de) |
| PT (1) | PT1441708E (de) |
| WO (1) | WO2003039525A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1441708T3 (da) | 2001-11-05 | 2009-07-06 | Krele Pharmaceuticals Llc | Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| RS52183B (sr) * | 2006-12-14 | 2012-10-31 | Teva Pharmaceutical Industries, Ltd. | Kristalna čvrsta baza razagilina |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| WO2011062614A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US20130165511A1 (en) * | 2010-09-01 | 2013-06-27 | TONIX Pharmaceuticals Holding Corp | Treatment for cocaine addiction |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| NZ747040A (en) | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| SG11201701995PA (en) | 2014-09-18 | 2017-04-27 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| AU2018383098B2 (en) | 2017-12-11 | 2024-12-12 | Tonix Pharma Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| KR20230175175A (ko) | 2020-11-30 | 2023-12-29 | 소프로시네 파마슈티칼스 리미티드 | 알코올 사용 장애(Alcohol Use Disorder)를 치료하기 위한 화합물 및 방법 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2567814A (en) * | 1948-03-26 | 1951-09-11 | Ayerst Mckenna & Harrison | Tetraethyl thiuram disulfide alcoholism treatment composition |
| US3155584A (en) * | 1962-12-03 | 1964-11-03 | Abbott Lab | Compositions and method of inhibiting monoamine oxidase and treating hypertension |
| SE404186B (sv) * | 1975-06-09 | 1978-09-25 | Astra Laekemedel Ab | Forfarande for framstellning av cyklopropanolderivat |
| US4678809A (en) * | 1985-02-01 | 1987-07-07 | Michael Phillips | Injectable fomulations of disulfiram for the treatment of alcoholism |
| US4565689A (en) * | 1985-04-12 | 1986-01-21 | Wirth Maschinen-Und Bohrgerate-Fabrik Gmbh | Method for treating the effects of alcohol |
| US4868218A (en) * | 1987-08-18 | 1989-09-19 | Buyske Donald A | Method of treating depression |
| US4861800A (en) * | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
| GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| US5192550A (en) * | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
| US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| US5128145A (en) * | 1990-06-13 | 1992-07-07 | Alza Corporation | Dosage form for Parkinson's disease, spasticity and muscle spasms |
| AU8760691A (en) * | 1990-10-01 | 1992-04-28 | Thomas E. Radecki | Drug therapy for alcohol abusers |
| HU209605B (en) | 1991-04-15 | 1994-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for production of wather-free transdermal preparation |
| WO1992021333A2 (en) * | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
| EP0520325A1 (de) | 1991-06-28 | 1992-12-30 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch |
| US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| EP0593807A1 (de) | 1992-10-22 | 1994-04-27 | LTS Lohmann Therapie-Systeme GmbH & Co. KG | Transdermales Pflaster zur Abgabe von basischen, flüchtigen pharmazeutischen Wirkstoffen und Verfahren zu ihrer Herstellung |
| US5242950A (en) * | 1992-04-23 | 1993-09-07 | Somerset Pharmaceuticals, Inc. | Treatment of macular degeneration |
| DE4428444A1 (de) * | 1994-08-11 | 1996-02-15 | Dresden Arzneimittel | Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen |
| US6319954B1 (en) | 1995-01-13 | 2001-11-20 | Somerset Pharmaceuticals, Inc. | S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions |
| BR9501972A (pt) * | 1995-05-09 | 1997-08-26 | Tostes Luiz Roberto Mallat | Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo |
| AU709323B2 (en) * | 1996-03-15 | 1999-08-26 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neuropathy by administering selegiline |
| DE69614888D1 (de) * | 1996-06-28 | 2001-10-04 | Dallet Etienne Romeuf Sauze Au | Durch muskelkraft angebtriebenen fahrzeug, insbesondere fahrrad |
| US6255497B1 (en) * | 1997-04-29 | 2001-07-03 | The Endowment For Research In Human Biology, Inc. | Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse |
| BR9814830A (pt) | 1997-10-28 | 2000-10-03 | Schering Corp | Método de redução de desejo em mamìferos |
| WO1999058124A1 (en) * | 1998-05-12 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| DK1441708T3 (da) | 2001-11-05 | 2009-07-06 | Krele Pharmaceuticals Llc | Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme |
-
2002
- 2002-11-04 DK DK02789421T patent/DK1441708T3/da active
- 2002-11-04 NZ NZ532583A patent/NZ532583A/en not_active IP Right Cessation
- 2002-11-04 AU AU2002354017A patent/AU2002354017B2/en not_active Ceased
- 2002-11-04 WO PCT/US2002/035376 patent/WO2003039525A1/en not_active Ceased
- 2002-11-04 EP EP02789421A patent/EP1441708B1/de not_active Expired - Lifetime
- 2002-11-04 US US10/287,153 patent/US20030087814A1/en not_active Abandoned
- 2002-11-04 PT PT02789421T patent/PT1441708E/pt unknown
- 2002-11-04 AT AT02789421T patent/ATE427745T1/de active
- 2002-11-04 DE DE60231896T patent/DE60231896D1/de not_active Expired - Lifetime
- 2002-11-04 CA CA2463987A patent/CA2463987C/en not_active Expired - Fee Related
-
2008
- 2008-06-25 US US12/145,792 patent/US8093300B2/en not_active Expired - Fee Related
-
2011
- 2011-12-30 US US13/340,999 patent/US8481599B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT1441708E (pt) | 2009-06-18 |
| CA2463987C (en) | 2011-03-08 |
| NZ532583A (en) | 2006-12-22 |
| EP1441708A1 (de) | 2004-08-04 |
| US20120101154A1 (en) | 2012-04-26 |
| WO2003039525A1 (en) | 2003-05-15 |
| EP1441708A4 (de) | 2007-05-23 |
| EP1441708B1 (de) | 2009-04-08 |
| US20090005441A1 (en) | 2009-01-01 |
| US20030087814A1 (en) | 2003-05-08 |
| US8093300B2 (en) | 2012-01-10 |
| CA2463987A1 (en) | 2003-05-15 |
| AU2002354017B2 (en) | 2007-08-16 |
| DK1441708T3 (da) | 2009-07-06 |
| US8481599B2 (en) | 2013-07-09 |
| DE60231896D1 (de) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000040235A3 (en) | Treatment of asthma with mek inhibitors | |
| DE60215787D1 (de) | Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern | |
| DE60005688D1 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
| MXPA04004170A (es) | Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9. | |
| ATE437653T1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
| EA200400966A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
| WO2005018535A3 (en) | Compositions and methods for treatment of severe acute respiratory syndrome (sars) | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| WO2005000213A8 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors | |
| DE60231896D1 (de) | Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus | |
| SE0301886D0 (sv) | New use V | |
| ATE411018T1 (de) | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) | |
| TW200505829A (en) | Protease inhibitors for coronaviruses and sars-cov and the use thereof | |
| ATE511655T1 (de) | Verfahren zur auswertung eines myelounterdrückungszustands | |
| EP1230919A3 (de) | Verwendung einer Zusammensetzung enthaltend ein Retinoid und ein ERB-Inhibitor zur Herstellung eines Medikaments zur Behandlung von Retinoid-Hautschäden | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| DK0942751T3 (da) | Præparater til behandling af perifere nuropatier indeholdende antidepressiver og/eller monoaminoxidase-inhibitorer og/eller vitamin B12 og/eller prekursere til eller inducere af en neurotransmitter | |
| ATE382346T1 (de) | Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten | |
| WO2002078639A3 (en) | A method of treating proliferative diseases using eg5 inhibitors | |
| WO2005084654A3 (en) | Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents | |
| ATE481104T1 (de) | Mittel zur behandlung von flaviviridae- infektionen | |
| ATE212552T1 (de) | Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten | |
| DE60334094D1 (de) | Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden | |
| SE0301883D0 (sv) | New use II | |
| DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1441708 Country of ref document: EP |